Log in

Webinar 2 - Hot Topics in schizophrenia

October 8, 2020 (19:00, UTC+2)

Global Times
10:00 (Los Angeles), 13:00 (New York), 18:00 (London), 19:00 (Paris), 2:00, Oct 23 (Tokyo)

Anthony Grace (USA)
Presentation Title:The Circuitry Of Schizophrenia: When Good Neurons Go Bad

Konstantinos N. Fountoulakis (Greece)
Presentation Title:
The Use And Usefulness Of Antipsychotic Medication In The Treatment Of Schizophrenia

Gabriella Gobbi (Canada)

Registration Fees per Webinar

  • CINP Member - $20
  • CINP Non-Member - $40
  • Student, Trainee, Fellow - $0 (Proof of student or post doc status is required at time of registration.)

Join the conversation online on Facebook, LinkedIn, or Twitter using our official hashtag: #CINPOnline

Anthony Grace, USA (Speaker)

Dr. Anthony A. Grace is a Distinguished Professor of Neuroscience and a Professor of Psychiatry and Psychology at the University of Pittsburgh.  He has been involved in translational research related to the dopamine system as it relates to the pathophysiology of psychiatric disorders for over 40 years.   His early work pioneered the mode of action of antipsychotic drugs and the identification and characterization of dopamine-containing neurons.  Currently, Dr. Grace’s  work involves the role of stress in pathophysiology, novel treatments for schizophrenia and its prevention, and the role of dopamine in affective disorders.  He has published more than 300 articles and is cited more than 45,000 times (H index 107). Dr. Grace has received several awards for his research, including the William K. Warren Award for Excellence in Schizophrenia Research, the Paul Janssen Schizophrenia Research Award and the Lilly Basic Scientist Award from the CINP, the Efron Award and the Axelrod Award from the ACNP, the Gold Medal award from the SOBP, and the Outstanding Basic Research award from the SIRS. Dr. Grace is one of a handful of individuals that not only performs important basic research, but can to integrate this work into testable models relevant to the human condition. 

Konstantinos N. Fountoulakis, Greece (Speaker)

Konstantinos N. Fountoulakis, MD, is Professor of Psychiatry at Aristotle University of Thessaloniki, AHEPA University Hospital, in Thessaloniki, Greece. 

He has coauthored more than 400 papers and more than 300 of them are published in high impact international journals with approx. 10,000 citations and h=54 (Publish or Perish). During the years 2016-8 he was ranked by expertscape.com within the top 25 world experts concerning Bipolar disorder (0.068%) and among the top 50 concerning suicidality (0.097%). He authored or co-authored a number of chapters in books, the book ‘Bipolar disorders: An Evidence-Based Guide to Manic Depression’ (Springer-Verlag 2015), co-edited the WPA book ‘Advances in Psychiatry vol 3’ (Springer-Verlag 2018), and the book ‘Psychobiology of behavior’ (Springer-Verlag 2019). He has received a number of national and international research awards, including the 2012 Kraepelin-Alzheimer medal of the University of Munich and the 2015 Excellence in Education Award of the WFSBP. Since 2014 he is honorary member of the WPA and currently serves as director of Cochrane Greece and head of the Section of Mental Health, Institute of Scientific Research of the Panhellenic Medical Association.

Gabriella Gobbi, Canada (Moderator)

Dr. Gabriella Gobbi is a Professor in the Department of Psychiatry, McGill University.

Dr. Gobbi leads a laboratory of basic science (Neurobiological Psychiatry Unit) and works as a Staff Psychiatrist at the Mood Disorder Clinic of the McGill University Health Center.
Her research approach spans from bench to bedside, bridging the gaps between fundamental and clinical research.

Dr. Gobbi received her MD (1991) and her specialty in Psychiatry and Psychotherapy (1995) from the Catholic University of Rome (Italy). She also earned a PhD in Neuroscience at the University of Cagliari (Italy) and finalized a post-doc at McGill University (Montreal, Canada) in 1998.

Dr Gobbi’s lab is interested in understanding the pathophysiology of major depression and sleep related disorders and in the discovery of new treatments and cures for them.
In particular, her laboratory is studying the short- and long-term effects of cannabis use in mood and anxiety, and the potential beneficial effects of the drugs acting on the endocannabinoid system (endogenous cannabis) in the cure of mental diseases. Her lab is also studying the effect of melatonin in mood, anxiety and sleep regulation in an effort to understand how novel selective ligands for melatonin receptors (called MT1 and MT2 receptors) can be used to treat seasonal depression, major depression, sleep disorders, as well as pain.
Dr. Gobbi is author of more than 100 highly cited manuscripts in high impact journals, 20 book chapters, one book and holds international patents in psychopharmacology.
She has won many prizes including the Canadian College of Neuropsychopharmacology (CCNP) Young investigator Award in 2012, the Venezia Prize in 2015 and the Sam Lal prize from the Boeckh Foundation in 2017. She has served as reviewer/editor for many journals, international grant agencies in Europe and the USA and has been invited to speak at conferences around the world.
Dr Gobbi served as an expert witness for the Canadian Senate (2012), the Ministry of Health (2019) and the Ministry of Justice (2019) of Quebec for the cannabis legislation, her studies on cannabis are included in the recommendation of Health Canada and have influenced policies raising the age of cannabis consumption from 18 to 21 yo.

©2021 CINP